 "SPARC slips 10% as USFDA rejects cancer drug application")
Shares of Sun Pharma Advanced Research Company (SPARC) slipped 10 per cent to Rs 172 on the BSE on Wednesday in an otherwise strong market after the US health regulator rejected the cancer drug application.
SPARC on Tuesday said the company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).
The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised, it added.
Abraxane is indicated for treatment of breast cancer, lung cancer among others.
As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form.
On outlook, in 2018-19 annual report, SPARC said it has been successful in obtaining USFDA approvals for Xelpros and Elepsia XR in FY 2018-19. SPARC has filed NDA for Taclantis. SPARC expects to have an increase in royalty income with the licensing of Elepsia XR and Taclantis.
SPARC on Tuesday said the company has received a Complete Response Letter (CRL) from the United States Food & Drug Administration (USFDA) for the new drug application (NDA) for Taclantis (Paclitaxel Injection Concentrate for Suspension).
The company is reviewing the CRL and intends to work with the USFDA as soon as possible to address the concerns raised, it added.
Abraxane is indicated for treatment of breast cancer, lung cancer among others.
As per the USFDA, a CRL is sent to an applicant if the agency determines that it will not approve the application or abbreviated application in its present form.
On outlook, in 2018-19 annual report, SPARC said it has been successful in obtaining USFDA approvals for Xelpros and Elepsia XR in FY 2018-19. SPARC has filed NDA for Taclantis. SPARC expects to have an increase in royalty income with the licensing of Elepsia XR and Taclantis.
At 11:01 am, SPARC was trading 8 per cent lower at Rs 176 on the BSE, as compared to a 0.86 per cent rise in the S&P BSE Sensex. A combined 1.35 million shares changed hands on the counter on the NSE and BSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%